Auriga Laboratories

Auriga Laboratories was a specialty pharmaceutical company based in Atlanta, Georgia, that focused on the development and commercialization of prescription products for the respiratory, dermatological, and pain management markets. The company's primary business model involved acquiring or licensing niche pharmaceutical products and utilizing a targeted sales force to market them to pediatric and primary care physicians. Its product portfolio notably included cough and cold treatments such as Levall and Aquatab, as well as several New Drug Application (NDA) candidates like Rezira and Zutripro. Although it operated as a publicly traded entity, Auriga faced significant financial and legal challenges that culminated in a Chapter 11 bankruptcy filing in 2008. The company is currently inactive, having liquidated its assets following the bankruptcy proceedings.